Rigel Pharmaceuticals (RIGL) EPS (Weighted Average and Diluted) (QoQ) (2010 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.88% |
| Dec 31, 2025 | 865.75% |
| Sep 30, 2025 | -55.49% |
| Jun 30, 2025 | 420.63% |
| Mar 31, 2025 | -22.22% |
| Dec 31, 2024 | 15.71% |
| Sep 30, 2024 | 1,266.67% |
| Jun 30, 2024 | 87.23% |
| Mar 31, 2024 | -1,040.00% |
| Dec 31, 2023 | 115.15% |
| Sep 30, 2023 | 13.16% |
| Jun 30, 2023 | -375.00% |
| Mar 31, 2023 | 97.41% |
| Dec 31, 2022 | -2,709.09% |
| Sep 30, 2022 | -37.50% |
| Jun 30, 2022 | 50.00% |
| Mar 31, 2022 | -14.29% |
| Dec 31, 2021 | -16.67% |
| Sep 30, 2021 | -50.00% |
| Jun 30, 2021 | -136.36% |
| Mar 31, 2021 | 283.33% |
| Dec 31, 2020 | -50.00% |
| Sep 30, 2020 | 20.00% |
| Jun 30, 2020 | -176.92% |
| Mar 31, 2020 | 226.52% |
| Jun 30, 2019 | -12.05% |
| Dec 31, 2012 | 19.44% |
| Sep 30, 2012 | -2.86% |
| Jun 30, 2012 | -7.87% |
| Mar 31, 2012 | 12.31% |
| Dec 31, 2011 | -48.00% |
| Sep 30, 2011 | 32.43% |
| Jun 30, 2011 | 6.93% |
| Mar 31, 2011 | -20.46% |
| Dec 31, 2010 | -134.38% |
| Sep 30, 2010 | 88.24% |